Article Figures & Data
Figures
- FIGURE 1.
Participants’ flow chart of groups A–C. PD = progressive disease.
- FIGURE 2.
Changes in WBC, hemoglobin, platelets, alanine aminotransferase, aspartate aminotransferase, and creatinine at baseline and at 1 and 4 wk after each cycle of PRRT in all patients (A and C) and in patients who completed 3 cycles of PRRT (B and D). Blue line = group A; red line = group B; green line = group C.
- FIGURE 3.
Representative images of partial remission in group A (A), group B (B), and group C (C).
Tables
Characteristic Group A (n = 12) Group B (n = 6) Group C (n = 14) Male 7 4 7 Female 5 2 7 Age (y) 53 ± 13 55 ± 10 50 ± 10 Primary tumor site Pancreas 3 3 7 Stomach 1 0 0 Duodenum 1 1 3 Rectum 2 0 2 Lung 1 1 0 Ovary 0 0 0 Carcinoma of unknown primary 0 0 1 Multiple endocrine neoplasia 0 1 0 Paraganglioma 2 0 1 Pheochromocytoma 2 0 0 Tumor grade 1 3 1 3 2 9 4 10 3 0 1 1 Number of lesions 1–10 4 2 6 1–20 2 2 1 >20 6 2 7 Metastases Liver 9 5 14 Bone 8 2 6 Lymph nodes 7 2 5 Lung 2 1 3 Prior treatment Surgery 9 2 7 Somatostatin analog 8 5 5 Everolimus 2 3 1 Tyrosine kinase inhibitor 1 5 9 Chemotherapy 2 3 6 Radiotherapy 1 1 1 Transarterial chemoembolization 1 1 3 Disease course (mo) 58 ± 64 58 ± 26 55 ± 25 Qualitative data are numbers; continuous data are mean ± SD.
Supplemental Data
Files in this Data Supplement:
